|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||15.60 - 15.72|
|52-week range||12.55 - 21.59|
|Beta (5Y monthly)||1.23|
|PE ratio (TTM)||8.50|
|Forward dividend & yield||0.76 (4.83%)|
|Ex-dividend date||29 Apr 2020|
|1y target est||22.84|
Ken Feinberg, who is mediating talks, said his "optimism knows no bounds," and that he expected the next set of cases scheduled for trial to soon settle. U.S. District Judge Vince Chhabria in San Francisco kept a stay on litigation until Nov. 2 and asked the parties for a status update at that time. Bayer, which acquired Roundup with its purchase of Monsanto for $63 billion in 2018, agreed in June to pay around $11 billion to settle the lawsuits, which have pummeled the company's share price.
Three of the cheapest stocks right now are an ad-tech company, a healthcare conglomerate, and a pharmacy giant. Let's take a look at why they are ideal choices for value investors. One of the cheapest stocks in the entire tech sector is French ad-tech company Criteo (NASDAQ: CRTO).
Chemicals giant Bayer and the U.S. government cooperated closely last year to lobby Thailand to reverse its ban on glyphosate, used in the company's controversial weedkiller Roundup, documents obtained by an environmental group and reviewed by Reuters show. The lobbying, including U.S. trade officials asking Bayer for information on Thailand's deputy agriculture minister, is detailed in more than 200 pages of partially redacted documents and emails, some directly between U.S. officials and a Bayer representative. The documents were obtained under the U.S. Freedom of Information Act by the Tucson, Arizona-based Center for Biological Diversity, which shared them with Reuters.